IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. 
Strategies and Opportunities to Stop Colon Cancer in Priority Populations (STOPCRC)
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Only an estimated 50 million US adults aged 50-75 are up-to-date on colorectal cancer (CRC) screening according to guidelines set by the federal government. CRC is 90% curable with timely detection and appropriate treatment of precancerous polyps; increased screening could reduce incidence by up to 50%. Groups least likely to undergo screening, those with minimal education, low income, low access to health care, recent immigrants or Hispanics, are the same people who frequently receive care at Federally Qualified Healthcare Center's (FQHCs). The use of fecal occult blood tests (FOBT) and fecal immunochemical tests (FIT) is exceedingly low in FQHCs (7-9% of patients in the past year) and far below national averages and target rates. Our results will provide valuable information on how to use electronic health record (EHR) resources to optimize guideline-based screening in FQHC clinics whose patient populations have disproportionately low CRC screening rates.
This project, in conjunction with the research team, will use an advisory panel to direct the research activities. The advisory panel will be made up of clinicians, leaders, researchers, and patients. The panel and team will guide the development of materials, the outreach to patients, and the research protocol to best reach FQHC patients who are due for colorectal cancer screening.
This project will be conducted in two phases, Phase I is conducting a pilot at two FQHC's, and Phase II is rolling out the intervention to between 20-30 clinics.
| Condition | Intervention |
|---|---|
| Colorectal Cancer | Other: Auto Plus |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Intervention Model: Parallel Assignment Masking: No masking Primary Purpose: Screening |
| Official Title: | Strategies and Opportunities to Stop Colon Cancer in Priority Populations |
- Increased Screening Rates [ Time Frame: up to 4 years (study period) ]Investigators will determine if the auto and auto-plus interventions increase the rates of screening compared to usual care at FQHC clinics.
| Estimated Enrollment: | 20000 |
| Study Start Date: | January 2013 |
| Estimated Study Completion Date: | December 2017 |
| Estimated Primary Completion Date: | September 2017 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
No Intervention: Usual Care
Clinics in usual care will go about clinic practices to complete recommended screening for colorectal cancer.
|
|
|
Active Comparator: Auto Plus
Clinics randomized to the Auto-Plus arm will engage in all activities (send an introductory letter to participants, then a FIT Kit, then a reminder letter encouraging the return of the FIT Kit) in addition to a PDSA (Plan Do Study Act) cycle to refine or improve their process.
|
Other: Auto Plus
Clinics randomized to the Auto-Plus arm will engage in all activities in the Auto arm (send an introductory letter to participants, then a FIT Kit, then a reminder letter encouraging the return of the FIT Kit) in addition to one other outreach effort.
|
Detailed Description:
Phase I (Pilot Aims)
- Aim 1 Conduct preliminary analyses of EHR data at two pilot clinics.
- Aim 2: Use codes and methods developed in Aim 1 to test the feasibility, reach, effectiveness, and cost of an EHR-based CRC screening intervention using a subset of 100 patients at each of two pilot clinics. We will use codes defined in Aim 1 to create a Solutions-based, Epic-integrated system to track CRC screening, mail FIT kits, and track patient test results and receipt of follow-up care. The system will be pilot-tested in two clinics.
- Aim 3: Use results from the pilot intervention to prepare for a large-scale, cluster-randomized pragmatic trial across 18 OCHIN clinics (see Phase II).
Transition from Phase I to Phase II
-Changes to our original proposal include going from a three arm to a two-arm pragmatic cluster trial with revised evaluation and power calculation and refinements to the intervention components for both usual care (now described as enhanced usual care) and the intervention (now described as enhanced auto).
Phase II (Full trial Aims)
- Primary Aim 1. Assess the effectiveness of a large-scale, two-arm CRC screening program among diverse CLINIC patients, and assess difference in CRC screening outcomes (overall and by age, sex, insurance status, Hispanic ethnicity/race). The intervention will consist of an automated data-driven, EHR-linked program for mailing FIT kits (with linguistically appropriate pictographic instructions and return postage) to patients due for CRC screening.
- Primary Aim 2. Assess the costs and long-term cost-effectiveness of the automated program.
We have also included two secondary aims:
- Secondary Aim 1. Assess adoption, implementation, reach and potential maintenance and spread of the program, using a mixed-method rapid assessment process, field notes, and other ethnographic data.
- Secondary Aim 2. Adapt and pilot-test the adaptation of STOP CRC in an alternate EHR platform, Allscripts, and develop an implementation guide to assist sites in adopting the program.
Eligibility| Ages Eligible for Study: | 50 Years to 74 Years (Adult, Senior) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Patients aged 50-74 with no evidence of a colonoscopy within 9 years or fecal testing within 11 months, and no history of colorectal disease will be eligible to receive a mailed FIT.
Exclusion Criteria:
- End Stage Renal Disease (ESRD)
- Hospice/Nursing Home
Contacts and LocationsPlease refer to this study by its ClinicalTrials.gov identifier: NCT01742065
| Contact: Amanda F Petrik, MS | 503-335-2483 | amanda.f.petrik@kpchr.org | |
| Contact: Jennifer S Rivilli, MA | 503-335-2462 | Jennifer.S.Rivilli@kpchr.org |
| United States, California | |
| Open Door Health Center | Recruiting |
| Arcata, California, United States, 95521 | |
| Contact: Joe Carroll 707-826-8633 | |
| United States, Oregon | |
| Mosaic Medical | Recruiting |
| Bend, Oregon, United States, 97701 | |
| Contact: Jaime Crandall 541-383-3005 | |
| Benton and Linn County Health Centers | Recruiting |
| Corvallis, Oregon, United States, 97330 | |
| Contact: Melanie Wiens 541-766-6366 | |
| Virginia Garcia Memorial Health Center | Recruiting |
| Hillsboro, Oregon, United States, 97124 | |
| Contact: Tanya Kapka, MD tanya.kapka@kpchr.org | |
| Sub-Investigator: Tanya Kapka, MD | |
| La Clinica Health Care | Recruiting |
| Medford, Oregon, United States, 97501 | |
| Contact: Simon Parker-Shames 541-535-6239 | |
| Community Health Center | Recruiting |
| Medford, Oregon, United States, 97504 | |
| Contact: Jackie Weber 541-773-3863 | |
| Multnomah County Health Department | Recruiting |
| Portland, Oregon, United States, 97214 | |
| Contact: Josue Aguirre 503-988-3663 | |
| Oregon Health and Science University | Recruiting |
| Scappoose, Oregon, United States, 97056 | |
| Contact: Dawn Hammel 503-418-4222 | |
| Principal Investigator: | Gloria Coronado, PhD | The Center for Health Research, Kaiser Permanente Northwest |
| Principal Investigator: | Beverly Green, PhD | Group Health Cooperative |
More Information
Publications:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | Kaiser Permanente |
| ClinicalTrials.gov Identifier: | NCT01742065 History of Changes |
| Other Study ID Numbers: |
UH3CA188640 ( U.S. NIH Grant/Contract ) 1UH2AT007782-01 ( U.S. NIH Grant/Contract ) |
| Study First Received: | December 3, 2012 |
| Last Updated: | June 2, 2017 |
| Studies a U.S. FDA-regulated Drug Product: | No | |
| Studies a U.S. FDA-regulated Device Product: | No | |
Keywords provided by Kaiser Permanente:
|
Colorectal Cancer Screening Cancer Screening Pragmatic Trial |
Additional relevant MeSH terms:
|
Colorectal Neoplasms Colonic Neoplasms Intestinal Neoplasms Gastrointestinal Neoplasms Digestive System Neoplasms Neoplasms by Site |
Neoplasms Digestive System Diseases Gastrointestinal Diseases Colonic Diseases Intestinal Diseases Rectal Diseases |
ClinicalTrials.gov processed this record on July 17, 2017